An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 4 news stories from 3 outlets.

Safety and efficacy data of ABP 501 have been confirmed in an open-label extension trial of the biosimilar.

Previous research has demonstrated the similarity of Amgen’s ABP 501 (Amjevita) to the reference adalimumab (Humira) and…

Previous research has demonstrated the similarity of Amgen’s ABP 501, Amjevita, to the reference adalimumab, Humira, and…

ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.